1,097 results on '"Fätkenheuer, Gerd"'
Search Results
52. On Taking a Different Route: An Unlikely Case of Malaria by Nosocomial Transmission
53. Repurposing QuantiFERON for Detection of Neutralizing Interferon-γ Autoantibodies in Patients With Nontuberculous Mycobacterial Infections
54. Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing
55. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial
56. Training in infectious diseases across Europe in 2021 – a survey on training delivery, content and assessment
57. Vertebral Osteomyelitis After Spine Surgery: A Disease With Distinct Characteristics
58. Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
59. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
60. Combination therapy with anti-HIV-1 antibodies maintains viral suppression
61. Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome
62. Immune response to mRNA ‐based COVID ‐19 booster vaccination in people living with HIV
63. Adressen
64. HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial
65. Adjunctive Therapy With Clindamycin in Streptococcal Infection
66. Monkeypox: Lessons from a large cohort
67. Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015
68. Übersichtsartikel: Klinische Infektiologie in Deutschland und Europa
69. Additional file 1 of Results of the Cologne Corona Surveillance (CoCoS) study – a cross-sectional study: survey data on risk factors of SARS-CoV-2 infection in adults
70. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
71. The “Choosing Wisely” initiative in infectious diseases
72. Low prevalence of DHFR and DHPS mutations in Pneumocystis jirovecii strains obtained from a German cohort
73. Vancomycin Minimum Inhibitory Concentration in Methicillin-Susceptible Staphylococcus aureus and Mortality: More Than Handwaving?
74. Publisher Correction: Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection
75. Infektiologie
76. Infektiologie
77. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study
78. Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations
79. Antiretroviral pill count and clinical outcomes in treatment‐naïve patients with HIV infection
80. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?
81. Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients
82. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery
83. Longitudinal Analysis of Distribution and Function of Plasmacytoid Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients
84. Maraviroc — die Studienlage
85. Geleitwort
86. The “Choosing Wisely”: initiative in infectious diseases
87. Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection
88. Implementing the Lolli-Method and pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools: a pilot project
89. Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons
90. Aerosolized Ribavirin for Patients With Cancer and Respiratory Syncytial Virus Infection
91. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study
92. SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma
93. Correction to: Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016
94. Surgical Procedure Time and Mortality in Patients with Infective Endocarditis Caused by Staphylococcus aureus or Streptococcus Species
95. CXCR3 Expression Pattern on CD4+ T Cells and IP-10 Levels with Regard to the HIV-1 Reservoir in the Gut-Associated Lymphatic Tissue
96. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
97. University Hospital Cologne - Management Pathway - Febrile Neutropenia
98. SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma
99. A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1
100. Phase II Study of Vicriviroc versus Efavirenz (Both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.